Mark Sullivan, Managing Director at MDGH, will be presenting on capital raising for a pre-NDA PRV candidate: moxidectin for onchocerciasis.  During his presentation he will discuss the development pathway of moxidectin and the unmet medical need being addressed.  He will also give an overview of the capital raising activities and time frames and review the global health impact obligations contained within the funding agreements.  Further, Mark will share his vision on the post PRV plans to build a sustainable NFP global health biotechnology company.

For more information PRV summit.